Free Trial

10 Best Penny Stocks to Buy Now - 5 of 10

 
 

Invivyd (NASDAQ:IVVD)

Number of Upgrades from Top-Ranked Analysts
4 (in the last 90 days)
Consensus Rating
Buy
Rating Score
3.2
Ratings Breakdown
5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$7.89 (1,676.9% Upside)

About Invivyd

Invivyd logoInvivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
11/21/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
11/20/2024Morgan StanleyLower Price TargetOverweight ➝ Overweight$9.50 ➝ $3.55
11/20/2024HC WainwrightLower Price TargetBuy ➝ Buy$15.00 ➝ $10.00
10/30/2024EF Hutton Acquisition Co. IUpgradeStrong-Buy
10/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
9/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
8/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
4/5/2024GuggenheimUpgradeNeutral ➝ Buy$9.00
 

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.